This study will evaluate an investigational drug called HMBD-002, alone or in combination with another drug (pembrolizumab), in people who have advanced cancer. The study consists of 2 parts. In the first part of the study, researchers aim to determine the highest tolerable dose of HMBD-002 alone and in combination with pembrolizumab in these patients. The purpose of the second part is to detect the activity of HMBD-02 alone or in combination with pembrolizumab. HMBD-002 is an antibody that targets and blocks the action of a specific protein (called VISTA) that inhibits the immune system from fighting off cancer cells; this type of therapy is called immunotherapy. It is hoped that targeting the VISTA protein with HMBD-002 either alone or combined with another immunotherapy antibody, pembrolizumab, will activate the immune system to fight cancer.
What is the full name of this clinical trial?
HMBD-002-V4C26-01: A Phase 1 Study of HMBD-002-V4C26 , a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies